Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Trevi Therapeutics Inc (TRVI)
NASDAQ:TRVI
RESEARCH TOOLSreports
Holding TRVI?
Track your performance easily
TRVI Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.27 - $4.68
Previous CloseN/A
Volume226.18K
Average Volume (3M)3.03M
Market Cap
$337.80M
Enterprise Value$273.90M
Total Cash (Recent Filing)$22.02M
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta0.98
Next Earnings
Mar 19, 2025EPS Estimate
-0.12Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.44
Shares Outstanding89,365,710
10 Day Avg. Volume487,023
30 Day Avg. Volume3,031,139
Standard Deviation0.44
R-Squared0.01
Alpha0.05
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-7.60
P/FCF Ratio0.00
Enterprise Value/Market Cap0.81
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-6.27
Forecast
1Y Price Target
$8.50Price Target Upside126.06% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
Trevi Therapeutics News
Bulls Say, Bears Say
Bulls Say
Clinical TrialsDiscontinuation rates in the CORAL trial have been well below expectations.
Efficacy And SafetyHaduvio demonstrated significant efficacy in reducing cough frequency, which could be transformational for the treatment of refractory chronic cough.
Market OpportunityA positive readout in the RIVER trial would be transformational for TRVI and represent a significant market expansion opportunity.
Bears Say
Drug EvaluationThe ph 2 POC RIVER trial in RCC is less certain as Haduvio has not yet been evaluated in this indication.
Drug SchedulingThere is a more cautious view on drug scheduling due to the higher diversion risk for an oral format.
Trial EnrollmentThe Human Abuse Potential trial experienced an unexpected slowdown of patient accrual, causing a small delay in full enrollment.
---
Ownership Overview
12.32% Insiders
5.49% Mutual Funds
1.53% Other Institutional Investors
73.87% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
TRVI FAQ
What was Trevi Therapeutics Inc’s price range in the past 12 months?
Trevi Therapeutics Inc lowest stock price was $1.27 and its highest was $4.68 in the past 12 months.
What is Trevi Therapeutics Inc’s market cap?
Trevi Therapeutics Inc’s market cap is $337.80M.
When is Trevi Therapeutics Inc’s upcoming earnings report date?
Trevi Therapeutics Inc’s upcoming earnings report date is Mar 19, 2025 which is in 59 days.
How were Trevi Therapeutics Inc’s earnings last quarter?
Trevi Therapeutics Inc released its earnings results on Nov 06, 2024. The company reported -$0.13 earnings per share for the quarter, missing the consensus estimate of -$0.12 by -$0.01.
Is Trevi Therapeutics Inc overvalued?
According to Wall Street analysts Trevi Therapeutics Inc’s price is currently Undervalued.
Does Trevi Therapeutics Inc pay dividends?
Trevi Therapeutics Inc does not currently pay dividends.
What is Trevi Therapeutics Inc’s EPS estimate?
Trevi Therapeutics Inc’s EPS estimate is -0.12.
How many shares outstanding does Trevi Therapeutics Inc have?
Trevi Therapeutics Inc has 89,365,710 shares outstanding.
What happened to Trevi Therapeutics Inc’s price movement after its last earnings report?
Trevi Therapeutics Inc reported an EPS of -$0.13 in its last earnings report, missing expectations of -$0.12. Following the earnings report the stock price went down -6.452%.
Which hedge fund is a major shareholder of Trevi Therapeutics Inc?
Among the largest hedge funds holding Trevi Therapeutics Inc’s share is Viking Global Investors LP. It holds Trevi Therapeutics Inc’s shares valued at 15M.
---
Trevi Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$8.50 (126.06% Upside)
$8.50 (126.06% Upside)
Blogger Sentiment
Bullish
TRVI Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 606.2K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.8%
Last 30 Days ▲ 10.4%
Last 30 Days ▲ 10.4%
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
178.51%
12-Months-Change
Fundamentals
Return on Equity
-59.65%
Trailing 12-Months
Asset Growth
-28.14%
Trailing 12-Months
Company Description
Trevi Therapeutics Inc
Trevi Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of treatment for neurologically mediated conditions. It focuses on the formulation of nalbuphine ER, which use to treat chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis, and levodopa-induced dyskinesia in patients with Parkinson's disease. The company was founded by Thomas R. Sciascia and Jennifer L. Good on March 17, 2011 and is headquartered in New Haven, CT.
---
TRVI Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted significant progress in clinical trials and a strong financial position with a substantial cash runway, which are positive indicators. However, these are tempered by an increased net loss and uncertainty regarding clinical outcomes, particularly in the IPF trial's SSRE analysis.Read More>---
TRVI Stock 12 Month Forecast
Average Price Target
$8.50
▲(126.06% Upside)
Technical Analysis
KalVista Pharmaceuticals
―
Xeris Pharmaceuticals
―
EyePoint Pharmaceuticals
―
Aldeyra Therapeutics
―
Forte Biosciences
―
BioCryst
―
Best Analysts Covering TRVI
1 Year
1 Year Success Rate
12/14 ratings generated profit
1 Year Average Return
+34.92%
reiterated a buy rating 11 days ago
Copying Mayank Mamtani's trades and holding each position for 1 Year would result in 85.71% of your transactions generating a profit, with an average return of +34.92% per trade.
---